Articles

Affichage des articles du juillet, 2018

Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018

mise a jour

Chinese Sorafenib (Bayer) Market Report, 2018-2022 - ResearchAndMarkets.com | Business Wire

Neuralstem Announces Presentation of Preclinical Data Demonstrating Neurogenic Compound NSI-189 Improves Cognition and Anxiety in a Mouse Model of Alzheimer’s Disease

BOURSE DE PARIS

PRE-MARKET

CHAMPION DU MONDE

SOINS DE SANTE a suivre

Advaxis Announces FDA Lifts Clinical Hold on Phase 1/2 Combination Study of Axalimogene Filolisbac with Durvalumab | Business Wire

NINLARO® (ixazomib)维持治疗3期试验达到主要终点,显示多发性骨髓瘤移植后患者的无进展生存延长有统计学意义 | Business Wire

Asia Pacific Cartilage Repair Market - Analysis from 2018-2024 - ResearchAndMarkets.com | Business Wire

CFN Media Exclusive Interview: Segra International's Cannabis Micropropagation Revolution

ObsEva SA to start trading today on the SIX Swiss Exchange

Clementia Appoints Experienced Financial Executive Steve Forte as Chief Financial Officer

PAVmed Names Shaun O’Neil Chief Commercial Officer | Business Wire

Dr. Reddy\'s Laboratories Announces the Launch of Hydroxychloroquine Sulfate Tablets, USP in the U.S. Market | Business Wire

Telehealth Market in the US - Industry Outlook and Forecast 2018-2023 - ResearchAndMarkets.com | Business Wire

Global Artificial Organs Market 2018-2022 | 10% CAGR Projection Over the Next Four Years | Technavio | Business Wire

Horizon Pharma plc to Release Second-Quarter 2018 Financial Results and Host Webcast on August 8, 2018 | Business Wire

FIT Biotech Oy: FIT Biotech Oy:n oman pääoman ehtoisten vaihtovelkakirjojen vaihtaminen osakkeiksi

Zynerba Pharmaceuticals Announces Top Line Results from ZYN001 THC-Prodrug Patch Phase 1 Study

CORRECTION FIT Biotech Oy: FIT Biotech\'s company site has been launched in Inderes.fi

Cue Health Receives ISO 13485 Certification

NEOVACS

GEVO...ça repart

Globus Medical Adds Two Innovative Solutions to Growing Trauma Portfolio

Antibe Therapeutics Releases Secondary Endpoint Data from Recent Phase 2B Gastrointestinal Safety Study for Lead Drug, ATB-346 | Business Wire

Poxel Announces Completion of Patient Enrollment for TIMES 1 Trial in the Phase 3 Registration Program for Imeglimin, an Investigational Therapeutic Agent for Type 2 Diabetes, in Japan | Business Wire

FIT Biotech Oy: FIT Biotech webcasts the company half-year financial report on September 6th 2018, at 10.00 AM.

Antibe Therapeutics Reports 2018 Year-End Financial and Operating Results | Business Wire

Alteogen and Lynkogen Enter into an Exclusive Option Agreement to Develop Proprietary Fusion Proteins for the Treatment of NASH and Metabolic Diseases | Business Wire